Ekso Bionics Acquires Equipois' Gravity Balancing Arm Technologies

Ekso Bionics Holdings, Inc., a leading global robotic exoskeleton company, announced today it acquired the gravity balancing arm technologies of Equipois, LLC, including the zeroG™ and X-Ar™ products. The all-stock transaction is a strategic acquisition for Ekso Bionics that is intended to expand the company's exoskeleton capabilities in the industrial market.

The patented technology behind the Equipois products enables workers to maneuver tools and other objects as if weightless. Some of the world's largest companies in aerospace, defense, automotive, heavy machinery, and other manufacturing industries are using this technology to enhance human performance and safety.

"Our ongoing field trials throughout this past year have clearly shown that now is the time to bring our exoskeleton technology to the industrial construction market. Companies are ready for exoskeletons, and their workers are eager to use them," said Russ Angold, president of Ekso Labs and co-founder of Ekso Bionics. "Adding the Equipois product portfolio provides us with core technology to meet customer demand and immediately expands our customer reach from construction to industrial and manufacturing end-users as well."

"It's exciting to see our technology go from helping people shoot movies to making peoples' lives better on the job site by helping to reduce fatigue, protect from injuries and increase productivity," said Garrett Brown, inventor of the Steadicam® camera stabilizer as well as the technology incorporated into the Equipois arms. "It's wonderful to see Ekso Bionics bringing their exoskeleton technology into the industrial construction market for able-bodied workers, much as they've already done for patients in medical rehabilitation. I'm excited to be a part of this new success."

Building on their installed base of over 600 units, Equipois has entered into supply and reseller arrangements with Ekso Bionics under which it will continue to sell the zero G™ and X-Ar™ products to their current manufacturing customers while Ekso Bionics will expand gravity balancing arm technology into industrial construction programs for human augmentation solutions.

"We definitely see this as the whole being greater than the sum of the parts," said John Allard, chief executive officer of the Allard Nazarian Group, the parent corporation of Equipois. "We are excited to be shareholders in such an innovative company that is taking human augmentation technology to the next level and into a market with such promising opportunity."

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Ekso Bionics. (2019, February 19). Ekso Bionics Acquires Equipois' Gravity Balancing Arm Technologies. AZoRobotics. Retrieved on November 21, 2024 from https://www.azorobotics.com/News.aspx?newsID=8049.

  • MLA

    Ekso Bionics. "Ekso Bionics Acquires Equipois' Gravity Balancing Arm Technologies". AZoRobotics. 21 November 2024. <https://www.azorobotics.com/News.aspx?newsID=8049>.

  • Chicago

    Ekso Bionics. "Ekso Bionics Acquires Equipois' Gravity Balancing Arm Technologies". AZoRobotics. https://www.azorobotics.com/News.aspx?newsID=8049. (accessed November 21, 2024).

  • Harvard

    Ekso Bionics. 2019. Ekso Bionics Acquires Equipois' Gravity Balancing Arm Technologies. AZoRobotics, viewed 21 November 2024, https://www.azorobotics.com/News.aspx?newsID=8049.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.